Mycopreneur

The Ousia team joins us today to pitch their Ousia Fountain at home CO2 extraction tabletop extraction equipment. Though this product and company are in fact real, we pitch it in a satirical skit aimed at taking down 'big tincture.' This unit is available for pre-order at https://ousialabs.com for $899 - the first 200 orders will receive $200 off. We hope this podcast is as educational and entertaining as it is commercial, and I welcome people to connect with the team at Ousia to find out more about what at home CO2 extraction looks like with the Ousia Fountain. Hosted on Acast. See acast.com/privacy for more information.

Mareesa Stertz is the Co-Founder of Lucid News and the creator of the 'Psychedelics and Storytelling' retreats and workshops. She joins me today to discuss how we can leverage the power of storytelling to program ourself with narratives that defy conventional social programing and which better suit us as empowered individuals. Please consider rating and reviewing the podcast wherever you're listening. Hosted on Acast. See acast.com/privacy for more information.

Manoj Doss is a postdoctoral psychedelic research scientist at Johns Hopkins University and is currently researching the impact of psilocybin on episodic memory.He joins the Mycopreneur Podcast today to provide insights into the underlying neural mechanisms occurring during a psilocybin mushroom-engendered psychedelic experience - We learn about the different regions of the brain and how they are uniquely impacted after the consumption of psychedelic mushrooms, and discuss the workflow of a psychedelic research scientists carrying out IRB approved research.Please consider rating and reviewing the episode wherever you're listening. Hosted on Acast. See acast.com/privacy for more information.

Masha Ty is the head of Corporate Growth and Education for Florida-based ACS Laboratory, an outfit which specializes in testing cannabis and mushroom products. We dive into the arc of Masha's journey from the traditional corporate world and into the cannabis and psychedelic industries, as well as the dynamics of transitioning an industry from an underground black market into a legal and regulated economy.Please consider rating and reviewing the podcast wherever you're listening. Hosted on Acast. See acast.com/privacy for more information.

Jeremy Gardner joins us on the Mycopreneur podcast to share insights about the roles of technology and venture capital in shaping the psychedelic ecosystem of the future. After tremendous early success as a crypto investor, Jeremy has diversified his investments into a range of asset classes and ventures - which includes the emergent psychedelic industry. We dive into a range of topics from artificial intelligence to the future of masculinity to psilocybin mushroom macrodoses, as well as considerations for where to invest in the emergent psychedelics space.Please consider rating, reviewing, and sharing the podcast with a friend. Hosted on Acast. See acast.com/privacy for more information.

Emily Eizen is a multimedia artist and cannabis entrepreneur in Los Angeles.Her work has been featured in High Times, Playboy, and Forbes among other platforms -She joins us on the Mycopreneur podcast to share insights about her creative process, define what equity in the cannabis and psychedelic space means to her, and tell us about how she broke into the cannabis industry.Please consider rating & reviewing the podcast wherever you're listening. Hosted on Acast. See acast.com/privacy for more information.

Joe Moore and Kyle Buller are the Founders of Psychedelics Today, the planetary hub for individuals, practitioners, and professionals exploring psychedelics. They join me to talk about the state of the psychedelics space, which they continue to shape after six years being at the forefront of it. We talk about their Vital training program for psychedelics for professional training in psychedelic therapy and integration, their upcoming Convergence conference from March 30-April 2, 2023 in Los Angeles, and why all of us should focus on ending the drug war and eradicating the DEA above and beyond our own personal pursuits in the space. Please consider rating, reviewing, and sharing the podcast. Hosted on Acast. See acast.com/privacy for more information.

Dustin Robinson is the Managing Principal of Iter Investments and their venture studio Nucleus.He has a background in law and has advised and invested in numerous companies across the cannabis and psychedelics space. On today's podcast, we learn what Dustin and the Iter team look for in a company before investing, why they've decided to launch a crowdfunding campaign for their data-driven Nucleus platform, and why he's still bullish on investing in the psychedelic space despite the poor performance of the market sector over the last year.Please consider rating, reviewing, and sharing the podcast wherever you're listening Hosted on Acast. See acast.com/privacy for more information.

The Award-winning mycologist filmmaker Hamilton Pevec returns to the Mycopreneur podcast to share intel about his recently released film Azurescens: Through A Blue Lens. This film was recently crowned Best Edutainment piece at the Fungi Film Festival, and follows the pilgrimage of mushroom foragers in search of the fabled Psilocybe azurescens mushroom in the Pacific Northwest of the United States while examining the role that these fungi play in the ecology of their ecosystem. Please consider rating, reviewing, and sharing the podcast wherever you're listening. Hosted on Acast. See acast.com/privacy for more information.

Justin Hanka is the Co-Founder and Chief Executive Director of MindBio Therapeutics, world leaders in microdosing of psychedelics,Justin joins the Mycopreneur Podcast from his home in Melbourne, Australia to discuss the rigorous scientific inquiry and data collection that MindBio therapeutics is conducting in Phase 2 clinical trials assessing the medical efficacy of microdosing LSD to treat Major Depressive Disorder. We discuss the process of clinical trials, the data collected from MindBio Therapeutics Phase 1 clinical trials, what regulators need in order to approve psychedelics as a treatment model for Major Depressive Disorder, and the toppling data that is eradicating lingering stigma against psychedelic medicines in the medical establishment and society at large.Please consider rating, reviewing, and sharing the podcast wherever you're listening.  Hosted on Acast. See acast.com/privacy for more information.